PDS Planning Inc Has $359,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

PDS Planning Inc raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,426 shares of the biopharmaceutical company’s stock after buying an additional 182 shares during the quarter. PDS Planning Inc’s holdings in Gilead Sciences were worth $359,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Nilsine Partners LLC grew its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. grew its holdings in shares of Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares in the last quarter. Financial Counselors Inc. grew its holdings in shares of Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Gilead Sciences by 3.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares in the last quarter. Finally, Institutional & Family Asset Management LLC grew its holdings in shares of Gilead Sciences by 10.3% during the 3rd quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 140 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.29% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Mizuho reduced their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Royal Bank of Canada dropped their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Cantor Fitzgerald dropped their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Barclays dropped their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. Finally, StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and an average target price of $84.71.

Gilead Sciences Trading Up 0.5 %

Shares of GILD traded up $0.31 during mid-day trading on Tuesday, reaching $67.26. 1,553,676 shares of the company were exchanged, compared to its average volume of 7,254,602. Gilead Sciences, Inc. has a 52 week low of $65.90 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The stock has a market capitalization of $83.74 billion, a PE ratio of 14.88, a PEG ratio of 0.92 and a beta of 0.19. The business has a 50 day simple moving average of $71.81 and a two-hundred day simple moving average of $76.51.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter last year, the business earned $1.67 earnings per share. Gilead Sciences’s revenue was down 3.7% compared to the same quarter last year. On average, analysts predict that Gilead Sciences, Inc. will post 6.55 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.58%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.